The Potential Use of Alzheimer's Drugs in the Clinics

There is a really large gap between our current clinical practice in terms of diagnosing and caring for patients with Alzheimer's disease. The implementation of this new class of therapies requires very intense surveillance, as you say, and the use of biomarkers. I think because the risks of ARIA are very real, we will need to be quite conservative in who is treated by these drugs. We're not just thinking about colonnestar inhibitors or mementine-like drugs that slightly enhance cognition. There will be some catching up to do but ultimatelyThis is really going to elevate care in entirely different ways.